Former President and Chief Executive Officer · Dianthus Therapeutics, Inc. (DNTH)

Jason Gardner

A named executive officer of Dianthus Therapeutics in every fiscal year CompBrief holds from FY2019 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$667,649

Salary $57,861Stock awards $0

FY2019: $1,651,001

4th of 7 named executive officers at Dianthus Therapeutics by FY2023 total.

7 named officers on file for Dianthus Therapeutics, FY2023

Jason Gardner’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing
  • DNTH’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Dianthus Therapeutics’s whole pay program stands against its peers

  • Dianthus Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on DNTH→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 11, 2024 (DEF 14A).

Free

Get Jason Gardner’s full pay file as a PDF — free

More than this page: up to 10 years of Jason’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Jason Gardner compensation by year

Dianthus Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Dianthus Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2023
Salary$515,000$57,861
Bonus$0$0
Stock awards$0$0
Option awards$903,764$0
Non-equity incentive$231,750$0
Pension and deferred compensation$0$0
All other$487$609,788
Total$1,651,001$667,649

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Dianthus Therapeutics, Inc. DEF 14A filed April 11, 2024, accession 0000950170-24-043693, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Dianthus Therapeutics, Inc. filed document, accession 0000950170-24-043693. Every figure is read from that document and cited to the page and table it appears in. Filed April 11, 2024.

$1.7M
$668K
FY19
FY23
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
Option43,541—$7.71
Option333,192—$9.49
Option148,607—$7.13

Per the Outstanding Equity Awards at Fiscal Year-End table in Dianthus Therapeutics, Inc.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.

Dianthus Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Stephen MahoneyFormer President, Chief Financial and Operating Officer$1,656,676
Thomas BeethamFormer Chief Legal Officer$1,571,434
Lisa OlsonFormer Chief Scientific Officer$1,128,013
Jason Gardner · this pageFormer President and Chief Executive Officer$667,649
Marino GarciaPresident and Chief Executive Officer$496,022
Simrat RandhawaChief Medical Officer$338,158
Ryan SavitzChief Financial Officer, Chief Business Officer and Treasurer$329,651

Board service

Dianthus Therapeutics board · FY2021
Director compensation in US dollars, as Dianthus Therapeutics reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2021$31,875—$156,093$0$187,968

Each year as the company reported it in Dianthus Therapeutics's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Dianthus Therapeutics pays directors a $35,000 cash retainer. As stated in Dianthus Therapeutics's FY2021 proxy.

The full Dianthus Therapeutics compensation record

free company brief

This page is one person within Dianthus Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Dianthus Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Dianthus Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jason Gardner's compensation dossier · One-time report. No refunds.